Among individuals with Rett syndrome, treatment with trofinetide was linked to improvements in caregiver-reported outcomes by ...

Scientists have developed a new transgene control system that shows early promise for treating rare brain disorder Rett syndrome.

Neurogene has reported encouraging efficacy results with its gene therapy for rare genetic disorder Rett syndrome, but investors' concerns about safety seem to be weighing on its share price.

Rebeca Reyes Diaz, a second-year student at the University of Nevada, Reno Honors College, is a dedicated researcher ...

Neurogene (NGNE) announced a peer-reviewed publication on its EXACT transgene regulation technology. The preclinical ...

as a potential treatment for Rett Syndrome. This decision follows strong preclinical data showing MB-204's sustained benets, outperforming Tronetide-the only FDA-approved treatment for the disease.

as a potential treatment for Rett Syndrome. This decision follows strong preclinical data showing MB-204's sustained benefits, outperforming Trofinetide-the only FDA-approved treatment for the ...

Learn more about whether ACADIA Pharmaceuticals Inc. or Alvotech is a better investment based on AAII's A+ Investor grades, ...

Taysha Gene Therapies, Inc.’s TSHA share price has dipped by 19.06%, which has investors questioning if this is right time to ...

Parents will participate in late April with Reverse Rett 2025 to raise funds to battle syndrome afflicting their daughter.